Evidence map›Paper›PMID 31654265›Full record

ArticleJournal of computer-aided molecular design2019

A computational study of the molecular basis of antibiotic resistance in a DXR mutant.

Fanny S Krebs, Jérémy Esque, Roland H Stote

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Computer-Aided Drug Design: An Update.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Fanny S KrebsInstitut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Institut National de La Santé et de La Recherche Médicale (INSERM), U1258 / Centre National de Recherche Scientifique (CNRS), UMR7104 / Université de Strasbourg, 1 rue Laurent Fries, P. Box 10142, 67404, Illkirch, CEDEX, France.
Jérémy EsqueInstitut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Institut National de La Santé et de La Recherche Médicale (INSERM), U1258 / Centre National de Recherche Scientifique (CNRS), UMR7104 / Université de Strasbourg, 1 rue Laurent Fries, P. Box 10142, 67404, Illkirch, CEDEX, France.
Roland H StoteInstitut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Institut National de La Santé et de La Recherche Médicale (INSERM), U1258 / Centre National de Recherche Scientifique (CNRS), UMR7104 / Université de Strasbourg, 1 rue Laurent Fries, P. Box 10142, 67404, Illkirch, CEDEX, France. rstote@igbmc.fr.ORCID 0000-0003-2230-7145
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteins of the independent mevalonate pathway for isoprenoid biosynthesis are important targets for the development of new antibacterial compounds as this pathway is present in most pathogenic organisms such as Mycobacterium tuberculosis, DPlasmodium falciparum and Escherichia coli, but is not present in mammalian species, including humans. Deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) is an important target in this pathway and the most effective DXR inhibitor to date is fosmidomycin, which is used to treat malaria and, more recently, tuberculosis. Recently, Armstrong C. M. et al. showed that a mutant of DXR, S222T, induces a loss of the fosmidomycin inhibition efficiency, even though the bacteria culture is still viable and able to produce isoprenoids. As this represents a potential fosmidomycin-resistant mutation, it is important to understand the mechanism of this apparent mutation-induced resistance to fosmidomycin. Here, we used molecular dynamics simulations and Molecular Mechanics/Poisson Boltzmann Surface Area analysis to understand the structural and energetic basis of the resistance. Our results suggest that the point mutation results in changes to the structural dynamics of an active site loop that probably protects the active site and facilitates enzymatic reaction. From the simulation analysis, we also showed that the mutation results in changes in the interaction energy profiles in a way that can explain the observed activity of the mutant protein toward the natural inhibitor deoxy-D-xylulose 5-phosphate. These results should be taken into consideration in future efforts to develop new therapeutic antibiotic compounds that target DXR.

Indexed as

Drug Resistance, MicrobialMolecular Dynamics SimulationMutationAldose-Ketose IsomerasesAnti-Bacterial AgentsBinding SitesEscherichia coliFosfomycinLigandsModels, TheoreticalMycobacterium tuberculosisPentosephosphatesProtein Conformation1-deoxy-D-xylulose 5-phosphate reductoisomeraseAldose-Ketose IsomerasesAnti-Bacterial AgentsFosfomycinfosmidomycinLigandsPentosephosphatesxylulose-5-phosphateDrug designDXRFree energy bindingMEPMM/PBSAMolecular dynamics simulationsMutation

Identifiers

PMID31654265
OpenAlexW2981858817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.